FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. An oncolytic herpes simplex virus (HSV) containing recombinant nucleic acid, which contains the first nucleic acid sequence encoding the attracting polypeptide, is presented, while the specified attracting polypeptide contains the first domain specific to the antigen expressed on the effector cell, and the second domain specific to the antigen expressed on the target cell, and the specified antigen expressed on the effector cell is CD3, and the specified antigen expressed on the target cell is PDL1. A pharmaceutical composition containing the specified oncolytic virus is also presented. In addition, a method for treating cancer is proposed.
EFFECT: invention expands the arsenal of drugs for cancer treatment.
10 cl, 10 tbl, 14 ex, 41 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| MODIFIED J-STRAIN | 2015 |
|
RU2761118C2 |
| NOVEL PROTEIN COMPOSITIONS OBTAINED BY RATIONAL DESIGN | 2019 |
|
RU2816719C2 |
| TRISPECIFIC BINDING MOLECULES FOR TREATING VIRAL HEPATITIS B INFECTION AND BOUND STATES | 2016 |
|
RU2733496C2 |
| CHIMERIC CYTOKINE RECEPTOR | 2016 |
|
RU2826122C1 |
| ISOLATED ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF CHIMERIC ANTIGEN RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR INCLUDING IT | 2019 |
|
RU2742000C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| CELL | 2014 |
|
RU2732236C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2015 |
|
RU2768019C2 |
